Overview


According to FutureWise analysis the market for alpha-1 antitrypsin deficiency augmentation therapy is expected to reach US$ 2.63 billion by 2031 at a CAGR of 6.10%.

Alpha-1 Antitrypsin Deficiency (AATD) augmentation therapy is a long-term treatment strategy for individuals with AATD, a genetic disorder that can lead to severe lung and liver diseases. This therapy involves regular infusions of purified alpha-1 antitrypsin (AAT) derived from human plasma. By increasing the levels of functional AAT in the bloodstream, augmentation therapy aims to restore the protective activity in the lungs and potentially improve liver function.

The process of augmentation therapy begins with a diagnosis, followed by a thorough evaluation to assess the severity of lung and/or liver involvement. Once eligible, individuals receive regular intravenous infusions of purified AAT, typically on a weekly or bi-weekly basis. During each infusion session, the AAT is slowly introduced into the bloodstream, and patients are closely monitored. Augmentation therapy must be acknowledged for its numerous advantages, including its ability to significantly slow down the rate of lung function decline and effectively reduce the frequency of respiratory infections. It may also have potential benefits for liver function in individuals with liver involvement. However, it's important to note that augmentation therapy does not provide a cure for AATD or reverse existing lung or liver damage.

FutureWise Market Research has published a report that provides an insightful analysis of alpha-1 antitrypsin deficiency augmentation therapy market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that alpha-1 antitrypsin deficiency augmentation Therapy Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Pfizer
  • Grifols S.A.
  • CSL Limited
  • Kamada Ltd.
  • Baxter
  • Takeda Pharmaceutical Company Limited
  • Abeona Therapeutics Inc.
  • GlaxoSmithKline Plc.
  • AstraZeneca
  • Boehringer Ingelheim GmbH
  • LFB Biomedicaments
  • Teva Pharmaceutical Industries Ltd.
  • Abeona Therapeutics
  • ProBioGen
  • Chiesi Pharmaceuticals
  • Curaxys
  • ProMetic Life Sciences

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market:

  • In May 2022, ArisGlobal acquires BRASS from Boehringer Ingelheim, integrating its data insights engine into LifeSphere® to advance pharmacovigilance and patient safety. The new integration will be called LifeSphere Clarity.

The market of alpha-1 antitrypsin deficiency augmentation therapy is shaped by several key factors. Firstly, there has been a notable increase in awareness and diagnosis of AATD, driven by advancements in medical knowledge and diagnostic techniques. This has resulted in a growing patient population seeking treatment options, thereby fueling the demand for augmentation therapy. Additionally, the rising prevalence of chronic obstructive pulmonary disease (COPD), closely linked to AATD, has further propelled the market growth. As COPD continues to be a significant cause of morbidity and mortality worldwide, the demand for augmentation therapy as a targeted treatment for AATD-related COPD is increasing. Research and development efforts have focused on improving formulations and delivery systems to enhance the convenience and effectiveness of the therapy, including the development of long-acting options. However, the high cost of treatment poses a challenge, with affordability being a crucial factor in determining access for patients. Measures such as insurance coverage and patient assistance programs are being explored to address this issue. Overall, the market dynamics of AATD augmentation therapy are driven by increased awareness, the growing prevalence of COPD, research advancements, and the need for cost-effective solutions to ensure wider patient access.

By Drug Type

  • Glassia
  • Aralast NP
  • Prolastin C
  • Zemaira/Respreeza

By Route of Administration

  • Oral
  • Injection
  • Inhalation

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America holds a dominant position in the global market for alpha-1 antitrypsin deficiency (AATD) augmentation therapy and is expected to maintain its position throughout the forecast period. This is primarily attributed to the increasing prevalence of AATD in the United States and Canada, as well as the strategic presence of key companies in the region. Additionally, awareness programs focusing on AATD diagnosis and treatment contribute to market growth. In the Asia Pacific region, government initiatives aimed at genetic disorders and critical illness diagnosis and treatment, along with a rising birth rate in developing countries, are driving market expansion and presenting significant opportunities for market players in the upcoming years.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market By Drug Type, By Route of Administration, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- Drug Type launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Glassia
        2. Aralast NP
        3. Prolastin C
        4. Zemaira/Respreeza

  • 8.   Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Injection
        3. Inhalation

  • 9.   Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Stores

  • 10.   North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Pfizer
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Grifols S.A.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. CSL Limited
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Kamada Ltd.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Baxter
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Takeda Pharmaceutical Company Limited
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Abeona Therapeutics Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. GlaxoSmithKline Plc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. AstraZeneca
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Boehringer Ingelheim GmbH
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. LFB Biomedicaments
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Teva Pharmaceutical Industries Ltd.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Abeona Therapeutics
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. ProBioGen
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Chiesi Pharmaceuticals
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Curaxys
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. ProMetic Life Sciences
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

Related Market

Alpha-1 Antitrypsin Deficiency Treatment Market

Read More
Partner

Our Clients